학술논문
MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors
Document Type
Abstract
Author
Source
In Value in Health July 2022 25(7) Supplement:S521-S521
Subject
Language
ISSN
1098-3015